Kyntra Bio Inc (KYNB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.55+0.71%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KYNB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | |
|---|---|---|---|
| Revenues | |||
| Revenues | — | 6.4 | 29.6 |
| Total Revenues | — | 6.4 | 29.6 |
| Cost of Revenues | 4.3 | 0.6 | 15.6 |
| Operating Expenses & Income | |||
| Selling, General & Admin | 27.7 | 27.7 | 49.3 |
| R&D Expenses | 22.9 | 23.5 | 95.7 |
| Operating Income | (50.3) | (45.9) | (150.4) |
| Earnings from Continuing Operations | |||
| Interest Expense | 9.3 | 8.8 | 8.2 |
| Other Non-Operating Income / Expenses | 4.3 | 2.9 | 5.3 |
| EBT, Incl. Unusual Items | (30.9) | (58.3) | (153.4) |
| Income Tax Expense | — | (0.1) | (0.3) |
| Earnings from Continuing Operations | (30.9) | (58.2) | (153.1) |
| Net Income | |||
| Net Income | 183.2 | 183.5 | (47.6) |
| Per Share | |||
| Basic EPS | 45.25 | 45.37 | (0.48) |
| Diluted EPS | 45.25 | 45.37 | (0.48) |
| Basic Weighted Avg Shares | 4.0 | 4.0 | 100.0 |
| Diluted Weighted Avg Shares | 4.0 | 4.0 | 100.0 |
| Supplemental | |||
| EBIT | (50.3) | (45.9) | (150.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.